encorafenib,
LGX818,
Encorafenib,
LGX818,
1269440-17-6,
LGX-818,
Encorafenib (LGX818),
UNII-8L7891MRB6,
LGX 818,
8L7891MRB6,
Carbamic acid, N-[(1S)-2-[[4-[3-[5-chloro-2-fluoro-3-[(methylsulfonyl)amino]phenyl]-1-(1-methylethyl)-1H-pyrazol-4-yl]-2-pyrimidinyl]amino]-1-methylethyl]-, methyl ester,
Encorafenib [USAN:INN],
Braftovi,
Braftovi (TN),
LGX-818(Encorafenib),
NVP-LGX818-NXA,
NVP-LGX818,
Encorafenib (JAN/USAN/INN),
GTPL7908,
SCHEMBL8228295,
CHEMBL3301612,
DTXSID00155347,
CMJCXYNUCSMDBY-ZDUSSCGKSA-N,
BDBM221688,
BCP08458,
EX-A1587,
methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate,
MFCD25976758,
s7108,
ZINC68249103,
CS-2289,
DB11718,
SB16926,
NCGC00378599-03,
AC-30230,
AS-35201,
HY-15605,
A13226,
D11053,
US9314464, 9,
Methyl N-[(2S)-1-({4-[3-(5-chloro-2-fluoro-3-methanesulfonamidophenyl)-1-(propan-2-yl)-1H-pyrazol-4-yl]pyrimidin-2-yl}amino)propan-2-yl]carbamate,
D0TK7R,
B1174,